Preliminary findings from a phase I, multicenter, open-label study of the anti-CD37 antibody-drug conjugate (ADC), IMGN529, in adult patients with relapsed or refractory non-Hodgkin lymphoma (NHL).

2014 ◽  
Vol 32 (15_suppl) ◽  
pp. 8526-8526 ◽  
Author(s):  
Anastasios Stathis ◽  
Kami J. Maddocks ◽  
Ian Flinn ◽  
Alex Mejia ◽  
Maria Lia Palomba ◽  
...  
Keyword(s):  
Phase I ◽  
Hodgkin Lymphoma ◽  
Adult Patients ◽  
Antibody Drug Conjugate ◽  
Open Label ◽  
Open Label Study ◽  
Label Study ◽  
Drug Conjugate ◽  
Non Hodgkin Lymphoma ◽  
Antibody Drug

scholarly journals DCDT2980S, an Anti-CD22-Monomethyl Auristatin E Antibody–Drug Conjugate, Is a Potential Treatment for Non-Hodgkin Lymphoma

2013 ◽  
Vol 12 (7) ◽  
pp. 1255-1265 ◽  
Author(s):  
Dongwei Li ◽  
Kirsten Achilles Poon ◽  
Shang-Fan Yu ◽  
Randall Dere ◽  
MaryAnn Go ◽  
...  
Keyword(s):  
Hodgkin Lymphoma ◽  
Potential Treatment ◽  
Antibody Drug Conjugate ◽  
Drug Conjugate ◽  
Non Hodgkin Lymphoma ◽  
Antibody Drug
Sign in / Sign up

Export Citation Format

Share Document